Citations

Clear

813 citation(s) found for "He, Helen".

Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials
Saj, Fen , Namayanja, Felicity K. , Xiao, Lianchun , Kelley, Robin Kate , Goyal, Lipika , Azad, Nilofer S. , Bachini, Melinda , Lindsey, Stacie , Pant, Shubham , Javle, Milind , Kelley, R Katie , Goyal, Lipika , Bachini, Melinda , Pant, Shubham , Javle, Milind M , Saj, Fen , Borad, Mitesh J. , Valle, Juan W. , Fashoyin-Aje, Lola

Mayo Clinic

Cancer | December 19, 2025 | Volume: 132 | Issue: 1 | Pages: No page available

10.1002/cncr.70227 | PMID 41417596 Get It

Abstract Background Eligibility criteria for clinical trials are crucial for maintaining safety and study integrity. However, overly restrictive criteria can result in unrepresentative trial populations, leading to gaps in understanding real‐world treatment efficacy. Addressing potentially modifiable exclusions (PMEs) could enhance trial accessibility and participation without compromising safety. Methods The authors retrospectively analyzed screen‐failed patients with biliary tract cancer or pancreatic cancer between August 2019 and November 2024 at The University of Texas MD Anderson Cancer Center. Screen‐failed patients were those who provided informed consent but did not participate for any reason. Clinical data were obtained from screening logs and electronic health records. PMEs were identified and validated by two independent medical oncologists. Results Of 585 screen‐failed patients from 18 trials, 509 were analyzed (367 with pancreatic cancer and 142 with biliary tract cancer) after excluding 76 because of incomplete data. Leading causes of screen failure were declined participation (19%), comorbidities (12%), suboptimal organ function (11%), absence of a biomarker (10%), and insufficient biospecimens (7%). Reasons for declining included preference for standard care (23%), travel (22%), and competing trials (5%). The authors identified 69 patients (13.6%) who had PMEs (primarily borderline laboratory abnormalities), including liver function (23%), kidney function (20%), platelet count (12%), hemoglobin (7%), and white blood cell count (6%) abnormalities. Other PMEs included previous or concurrent malignancies (9%) and viral hepatitis (4%). PMEs were evenly distributed across trials. Conclusions Rigid eligibility criteria exclude stable patients who might benefit from investigational treatments. Easing criteria related to incidental or asymptomatic laboratory abnormalities could broaden trial accessibility and improve enrollment in populations that are more representative of real‐world use.
NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025
Mehren, Margaret von, Kane, John M., Armstrong, Samantha A., Balach, Tessa, Bishop, Andrew J., Buehler, Darya, Carr-Ascher, Janai, Choy, Edwin, Cipriano, Cara, Connolly, Mary, Dann, Amanda, Davis, Elizabeth J., Dry, Sarah, Eulo, Vanessa, Ganjoo, Kristen N., Gonzalez, Ricardo J., Viveiros, Pedro A. Hermida De, Hitchcock, Ying J., Kim, Edward, Lefler, Daniel, Liebner, David, McCarter, Martin, McGarry, Sean V., Mesko, Nathan W., Meyer, Christian, Motamedi, Kambiz, Movva, Sujana, Pappo, Alberto S., Pollack, Seth M., Poppe, Matthew, Riedel, Richard F., Robinson, Steven, Schuetze, Scott M., Sicklick, Jason K., Tseng, William W., Weiss, Mia C., Zimel, Melissa, Hang, Lisa E., Bergman, Mary Anne, Diwan, Zeenat, Pappo, Alberto S. , Riedel, Richard F. , Riedel, Richard F , Mehren, Margaret von, Kane, John M., Armstrong, Samantha A., Balach, Tessa, Bishop, Andrew J., Buehler, Darya, Carr-Ascher, Janai, Choy, Edwin, Cipriano, Cara, Connolly, Mary, Dann, Amanda, Davis, Elizabeth J., Dry, Sarah, Eulo, Vanessa Anne , Ganjoo, Kristen N., Gonzalez, Ricardo J., Viveiros, Pedro A. Hermida De, Hitchcock, Ying J., Kim, Edward, Lefler, Daniel, Liebner, David, McCarter, Martin, McGarry, Sean V., Mesko, Nathan W., Meyer, Christian, Motamedi, Kambiz, Movva, Sujana, Pollack, Seth M., Poppe, Matthew, Robinson, Steven, Schuetze, Scott M., Sicklick, Jason K., Tseng, William W., Weiss, Mia C., Zimel, Melissa, Hang, Lisa E., Bergman, Mary Anne, Diwan, Zeenat

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 17, 2025 | Volume: 23 | Issue: 12 | Pages: 498-506

10.6004/jnccn.2025.0058 | PMID 41671462 Get It

The treatment landscape for soft tissue sarcomas (STS) is evolving constantly. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for STS specific to surgical management and systemic therapy recommendations for various subtypes.
Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology
Abu‐Rustum, Nadeem R. , Campos, Susana M. , Amarnath, Sudha, Barber, Emma L. , Bradley, Kristin , Brooks, Rebecca , Chon, Hye Sook, Damast, Shari , Fisher, Christine M. , Frederick, Peter J., Gaffney, David K. , Giuntoli, Robert , Glaser, Scott , Howitt, Brooke E. , Kendra, Kari , Landrum, Lisa M. , Mantia-Smaldone, Gina , Mariani, Andrea , Nagel, Christa , Nieto, Karina , Nwachukwu, Chika , Podoll, Mirna, Rodabaugh, Kerry J. , Salani, Ritu , Schorge, John O., Schuetze, Scott M. , Siedel, Jean , Sisodia, Rachel , Soliman, Pamela T. , Ueda, Stefanie , Urban, Renata R. , Wyse, Emily , McMillian, Nicole R., Arend, Rebecca C. , Chino, Junzo , Crispens, Marta Ann , Gaillard, Stéphanie , Lea, Jayanthi Sivasothy , Lee, Nita Karnik , Mutch, David G. , Nekhlyudov, Larissa , Sambandam, Vaishnavi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 17, 2025 | Volume: 23 | Issue: 12 | Pages: 549-573

10.6004/jnccn.2025.0057 | PMID 41671440 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cervical Cancer provide diagnostic workup, staging, and various treatment recommendations for cervical cancer based on clinical and surgical staging. This selection from the NCCN Guidelines for cervical cancer specifically focuses on diagnosis and workup, principles of staging and surgery, and primary treatment recommendations for early-stage and advanced disease and provides a detailed overview of systemic therapy recommendations for cervical cancer.
Prospective, randomized dose-escalation trial with proton-based radiation for skull base and cervical spine chondrosarcomas: 30-year outcomes from PROG 85-26
Ioakeim‐Ioannidou, Myrsini, Yeap, Beow Y., Soetan, Z. , Hegazy, Rana , Todary, Engy S. , Tejada, Athena, Adams, Judith E., Kooy, Hanne M., Zieminski, Stephen, Nielsen, G. Petur, Hung, Yin P. , Rosenberg, Andrew , Shankar, Ganesh M. , Cunnane, Mary E. , Chang, Yuh-Shin , Gardner, Paul A. , Giap, Fantine , DeLaney, Thomas F. , Hug, Eugen B., MacDonald, Shannon M. , Packard, Daniel, Hung, Yin P , Kim, Daniel W. , Packard, Daniel George , Hegazy, Rana, Adams, Judith, Depauw, Nicolas , Rosenberg, Andrew, Tobert, Daniel G , Curry, William T. , Coté, Gregory M. , Kelly, Hillary R. , Chen, Yen‐Lin , Liu, Kevin X , Shih, Helen A.

Mayo Clinic

Neuro-Oncology | December 17, 2025 | Volume: 28 | Issue: 4 | Pages: 968-977

10.1093/neuonc/noaf289 | PMID 41414803 Get It

Abstract Background To determine if dose escalation improves outcomes for chondrosarcomas (CHS) of the base of the skull (BOS) and the cervical spine (CS). Methods A prospective, randomized, dose-escalation trial was designed for patients with CHS of the BOS and CS. Patients were randomly assigned to 70 Gy (RBE) or 76 Gy (RBE). The primary endpoint was local failure (LF). Secondary endpoints included overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), and treatment-related toxicities. Results Between 1987 and 2007, 105 patients were randomized, median follow-up was 29.2 years (IQR, 26.7-32.4). Forty-six patients were assigned to 70 Gy (RBE) and 59 were assigned to 76 Gy (RBE). LF at 5-, 10-, and 20 years were 7%, 9%, and 11% for 70 Gy (RBE), and 10%, 15%, and 19% for 76 Gy (RBE) (P = .16). Like LF rates, there was no benefit in dose escalation for OS (P = .28) and CSS (P = .22). Progression-free survival at 5-, 10-, and 20 years was 93%, 89%, and 77% for the low-dose group and 83%, 71%, and 59% for the high-dose group (P = .069). Late RT injury ≥ grade 3 was reported in a total of 19 (18%) patients across both dose levels, with 11% in the low-dose group and 24% in the high-dose group (P = .13). Conclusions This is the first and largest trial of patients with grade I/II BOS and CS CHS evaluating dose escalation for tumor control. Proton-based RT is effective and safe for these tumors, but there is no apparent benefit in dose escalation. Clinical Trial Information NCT00592748.
Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201
Kam, Audrey E , Meropol, Neal J. , Giantonio, Bruce J. , Diasio, Robert B. , Flynn, Patrick J. , Catalano, Paul J. , Hartner, Lee , Rowland, Kendrith M. , Song, Wei , Mulcahy, Mary F. , Whitehead, Robert P. , Petrelli, Nicholas J. , O’Dwyer, Peter J , Cella, David , Benson, Al B. , Catalano, Paul J , Cella, David , Benson, Al , Kam, Audrey E , Zhao, Fengmin , Sinicrope, Frank A. , Mayer, Robert J. , O’Dwyer, Peter J. , Hamilton, Stanley R.

Mayo Clinic

The Oncologist | December 13, 2025 | Volume: 31 | Issue: 1 | Pages: No page available

10.1093/oncolo/oyaf416 | PMID 41397917 Get It

Abstract Background Adjuvant 5-FU monotherapy was previously the standard treatment for stage II/III rectal cancer. This study compared adjuvant FOLFIRI, FOLFOX, and 5-FU/LV. Methods Eligible patients had T3-T4 N0 or Tany N1-3 rectal adenocarcinoma ≤12 cm from the anal verge and received pre-operative or postoperative 5-FU chemoradiotherapy (CRT). Patients were randomized to adjuvant FOLFIRI (8 cycles), FOLFOX (8 cycles), or 5-FU/LV weekly (6/8 weeks; 3 cycles). The trial planned to enroll 3,150 patients but was closed early following activation of an alternative adjuvant rectal cancer study including bevacizumab (E5204). The primary endpoint was overall survival (OS); secondary endpoints included disease-free survival (DFS), sphincter preservation, tolerability, and quality of life (QOL). Results The trial enrolled 225 patients (179 randomized) before early closure. Grade 3/4 toxicity occurred in 59%, with neutropenia, leukopenia, and diarrhea being the most common. At a median follow-up of 9.7 years, no significant OS or DFS differences were observed. The rate of sphincter preservation was numerically higher with FOLFIRI and FOLFOX versus 5-FU/LV, but the difference was not statistically significant. Conclusion FOLFOX and FOLFIRI can be safely administered after CRT in rectal cancer patients safely with expected toxicities. Due to early trial closure and small sample size, the survival analysis was underpowered to detect a significant difference between regimens. ClinicalTrials.gov identifier NCT00068692
0.05% Chlorhexidine gluconate is not associated with infection in antibiotic impregnated inflatable penile prosthesis surgery: results from a large multi-institutional collaborative
Ivan, Samuel , Chawareb, Elia Abou , Hammad, Muhammed, Lesgart, Michael , Baird, Bryce , Bajic, Petar , Barham, David W. , Bernie, Helen Levey, Chung, Paul, Cowan, Ketch , Dominick, Zayda, Good, J , Hsieh, Michael H. , Im, Brian H. , Kadakia, Y , Kohler, T, Lentz, Aaron , Mass-Lindenbaum, Marcelo , Morey, Allen F, Perito, Paul , Sadeghi‐Nejad, Hossein , Schammel, Joshua , Shridharani, Anand, Sarantos, Nicklas, Suarez‐Sarmiento, Alfredo, Warner, J Nicholas, Welliver, Charles E, Ziegelmann, M, Yafi, Faysal A, Gross, Martin , Simhan, Jay, Hammad, Muhammed , Ivan, Samuel J , Abou Chawareb, Elia , Helo, Sevann , Hammad, Muhammed A M , Bernie, Helen L. , Bole, Raevti , Kadakia, Yash , Morey, Allen F. , Nguyen, Vi , Pereira, Thairo Alves , Sarantos, Nicklas , Welliver, Charles , Ziegelmann, M, Yafi, Faysal A. , Simhan, Jay

Mayo Clinic

The Journal of Sexual Medicine | December 12, 2025 | Volume: 23 | Issue: 1 | Pages: No page available

10.1093/jsxmed/qdaf368 | PMID 41489194 Get It

Abstract Background 0.05% Chlorhexidine gluconate (CHG) is now commonly used as an antiseptic irrigation for inflatable penile prosthesis (IPP) surgery. Limited in vitro data suggest compatibility of 0.05% CHG with antibiotic impregnated IPP devices; however, very little clinical research exists to guide use of 0.05% CHG in this population. Aim Assess the relationship of 0.05% CHG and antibiotic impregnated IPP infection in a large multi-institutional cohort. Methods We retrospectively reviewed a multi-institutional cohort of patients who underwent antibiotic impregnated IPP implantation. We identified cases using intraoperative 0.05% CHG and an equal number of consecutive control cases without 0.05% CHG use from each center for comparison. The primary outcome was IPP infection requiring explantation. Patient demographics and surgical variables were analyzed using chi-square tests and multivariable logistic regression to identify variables associated with infection. Outcomes The primary outcome was IPP infection requiring device explanation. Results Among 14 participating institutions, 761 cases using an antibiotic impregnated IPP were analyzed. Of these, 348 (45.7%) had 0.05% CHG used during the case. Median follow-up was 4 months (interquartile range 1-12) for the 0.05% CHG group and 8 months (interquartile range 2-21) for the control group. Intraoperative 0.05% CHG utilization was not associated with antibiotic impregnated IPP infection rate (1.9% vs. 2.0%, P = .9). On multivariable analysis, prior IPP infection (OR 6.32, 95% CI 1.32-30.2, P = .021) and prior priapism (OR 10.01, 95% CI 1.18-89.7, P = .039) were associated with increased infection risk. Clinical implications The use of 0.05% CHG irrigation with antibiotic impregnated IPPs was associated with similar infection rates compared to antibiotic irrigation. Strengths and limitations Limitations include the use of a historical comparator cohort which may introduce unknown confounders, practice variation between multiple sites, shorter follow-up in the 0.05% CHG cohort, and the low incidence of IPP infection which may limit statistical power despite a large sample. The major strengths include the large, multi-institutional cohort, and the use of consecutive patients to minimize selection bias. Conclusion 0.05% CHG utilization was not associated with infection rates in antibiotic impregnated IPPs.
(046) Collagenase Clostridium Histolyticum for Ventral Curvature of the Penis Due to Peyronie’s Disease: Updated Results From a Noninterventional, Retrospective, Multicenter Study
Ziegelmann, Matthew , Cordon, B, Bennett, R, Yafi, FA, Bajic, P, Bennett, NE, Bernie, Helen L. , Mass-Lindenbaum, Marcelo , Hammad, Mustafa , Gumpf, K, Tursi, Jennifer, Hurley, David , Rezakhani, T, Ayad, M, Khera, M, Kava, B., Cordon, Billy H. , Islam, M, Tatem, Andrew J. , Bennett, R, Hammad, M, Andrews, J, Mills, James L.

Mayo Clinic

The Journal of Sexual Medicine | December 9, 2025 | Volume: 22 | Issue: Supplement_4 | Pages: No page available

10.1093/jsxmed/qdaf320.046 Get It

Abstract Introduction While most patients with Peyronie’s disease (PD) present with dorsal or lateral curvature, a significant number have ventral curvature (VC). These patients face limited treatment options, as they were excluded from initial clinical trials of collagenase clostridium histolyticum (CCH) due to safety concerns related to the proximity of the injection site to the urethra. However, urethral involvement is rare, as PD plaques develop in the tunica albuginea rather than the corpus spongiosum surrounding the urethra. Moreover, multiple prospective and retrospective studies have demonstrated favorable outcomes with CCH treatment in men with VC. Objective To evaluate the effectiveness and safety of CCH in men with PD and VC in a multicenter, real-world, retrospective study. Methods This is an ongoing phase 4, multicenter, retrospective review of medical records from 15 US physician sites. Eligible patients consisted of patients who are: age ≥18 years with a diagnosis of VC in PD with a palpable plaque that was treated with CCH from 2014 to the study start date at each site. Patients missing baseline (BL; pretreatment) or final (last measurement within 6 months of final CCH treatment) penile curvature measurements were excluded. Effectiveness endpoints included percentage change in VC from BL to last visit, mean change in VC (in degrees) from BL to last visit, and proportion of patients with ≥30% improvement in VC from BL to last visit. Safety was assessed as proportions of patients reporting treatment-related adverse events (TRAEs) throughout the study period. Results As of April 22, 2025, there were 116 patients with mean (SD) age of 58 (10.3) years who were eligible for analysis. Mean baseline VC decreased from 58 degrees to 37 degrees at last visit (37% improvement). An improvement in VC of ≥30% was seen in 73/116 (63%) of patients, with 81/116 (69.8%) experiencing ≥20% improvement. At least 1 TRAE was reported by 12 (10%) patients. TRAEs were mild-to-moderate in severity in 9 (75%) patients and unknown in 3 patients, with most events (14/17 [82%]) related to injection site reactions. As of the data cut, there were no treatment-related serious or treatment-related severe AEs, no reports of urethral involvement or injury, and no reports of corporal rupture. Conclusions Men with PD who present with ventral curvature represent an underserved patient population. Concerns about potential urethral injury pose a significant barrier to both minimally invasive and surgical treatments, thereby limiting available therapeutic options. These updated results from a multi-institutional real-world clinical cohort align with previous findings, and demonstrate that the clinical effectiveness and safety profile of CCH is consistent with the profile of CCH seen in other clinical presentations of PD. Disclosure Yes, this is sponsored by industry/sponsor: Endo USA, Inc Clarification: Industry initiated, executed and funded study Any of the authors act as a consultant, employee or shareholder of an industry for: Endo USA, Inc.
(036) Irrigation With 0.05% Chlorhexidine Gluconate Associated With Hydrophilic Inflatable Penile Prosthesis Infection: A Large Multi-Institutional Cohort Study
Han, Demin , Bajic, P, Barham, David , Bernie, Helen L. , Chung, P, Kohler, T, Lentz, A, Morey, Allen F. , Perito, Paul , Sadeghi‐Nejad, Hossein , Shridharani, A, Yafi, FA, Simhan, J, Han, D, Chawareb, Elia Abou , Eftekharzadeh, Sahar , Ivan, Samuel , Hammad, M, Chung, Paul H. , Helo, Sevann , Kohler, T, Morey, Allen F. , Shridharani, Anand, Welliver, Charles , Gross, Martin , Simhan, Jay

Mayo Clinic

The Journal of Sexual Medicine | December 9, 2025 | Volume: 22 | Issue: Supplement_4 | Pages: No page available

10.1093/jsxmed/qdaf320.036 Get It

Abstract Introduction 0.05% Chlorhexidine Gluconate (CHG) has gained popularity as an irrigant and dip for inflatable penile prosthesis (IPP) surgery. Prior in vitro data is conflicting on the impact of CHG use with hydrophilic coated devices. Objective We sought to identify possible associations between CHG use and hydrophilic IPP infection rate. Methods We conducted a retrospective cohort study of 2,933 patients undergoing IPP implantation across 14 referral centers. Data collection spanned from January 1, 2017 to March 1, 2024. Each surgeon contributed patients who underwent IPP implantation with CHG used as an irrigant and/or dip as well as an equal number of consecutive control patients without CHG use. The primary outcome was IPP explant for postoperative infection. Univariable analysis was used to compare patient demographics, and logistic regression analysis was performed to assess factors associated with infection. Results Hydrophilic devices were implanted in 2,150 patients. Median follow-up for non-CHG patients was 13 months (IQR 18) and four months (IQR 9) for CHG patients. The incidence of infection with intraoperative CHG use was significantly higher compared to those without CHG use (4.6%, 46/1,001 vs. 2.1%, 24/1,148, p<0.001). On multivariable logistic regression analysis, intraoperative CHG use was associated with infection (OR 2.07, 95% CI 1.24-3.47, p=0.01). Additional variables associated with infection included immunosuppression, prior IPP infection, prior priapism, and revision surgery (p<0.01, Table). On subgroup analyses, the increased infection risk of CHG was most clear when CHG was used as both irrigation and dip (OR 2.03, 95% CI 1.19-3.46, p=0.01) and when CHG was used during revision surgery (OR 3.36, 95% CI 1.15-9.82, p=0.03). Conclusions In a large multi-institutional cohort, intraoperative CHG use was associated with an elevated incidence of hydrophilic IPP infection. Providers may take these findings into consideration when performing IPP surgery with hydrophilic devices, especially during revision surgery. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Coloplast Corporation and Boston Scientific
New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging System
Kirkwood, Amy A. , Yohannan, Binoy , Theodorakakou, Foteini , Weverling, Flores , Simone, Valeria Di , Kumar, Shaji , Petropoulos, Ιoannis , Cohen, Oliver , Stamatelopoulos, Κimon , Whelan, Carol , Venneri, Lucia , Fontana, Marianna , Mahmood, Shameem, Schwotzer, Rahel , Wechalekar, Ashutosh , Khwaja, Jahanzaib , Milani, Paolo , Yohannan, Binoy , Theodorakakou, Foteini , Weverling, Flores , Di Simone, Valeria , Kumar, Shaji K , Petropoulos, Ioannis , Mussinelli, Roberta , Oerlemans, Marish I F J , Muchtar, E , Stamatelopoulos, Kimon , Gertz, Morie A , Fontana, Marianna , Minnema, Monique C , Dispenzieri, Angela , Palladini, Giovanni , Kastritis, Efstathios , Wechalekar, Ashutosh D. , Gillmore, Julian D , Milani, Paolo , Ravichandran, Sriram , Mussinelli, Roberta , Oerlemans, Marish I.F.J. , Muchtar, Eli , Lachmann, Helen J. , Gillmore, Julian D. , Briasoulis, Αlexandros , Gertz, Morie A. , Dispenzieri, Angela , Palladini, Giovanni , Kastritis, Efstathios

Mayo Clinic

Journal of Clinical Oncology | December 7, 2025 | Volume: 44 | Issue: 4 | Pages: 311-320

10.1200/jco-25-02558 | PMID 41353737 Get It

PURPOSE Outcomes in systemic light chain (AL) amyloidosis have improved with modern therapy limiting utility of existing risk stratification models. We validate a new staging system, incorporating longitudinal strain (LS) to the biomarker-based (NT-proBNP and Troponin-T) staging system in the contemporary treatment era (2015-2024). METHODS AL International Staging System (AL-ISS) was derived from a cohort of patients with AL amyloidosis from the UK National Amyloidosis Centre (2015-2019). The model was validated in patient cohorts from Europe (Greece, Italy, the Netherlands, and Switzerland), the United States (2015-2024), and the United Kingdom (2020-2024). RESULTS In total, 2,493 patients were included (derivation, n = 573; validation n = 1,920). In a multivariable model for the derivation cohort, LS ≥ –9% and cardiac biomarkers at previously validated thresholds (NT-proBNP 332 ng/L and 8,500 ng/L and high-sensitivity troponin T ≥ 50 ng/L) were independent poor prognostic factors stratifying patients into stages I, II, IIIA, IIIB, and IIIC. In the validation cohort, the patient stages were stage I: 317 (17%), II: 782 (41%), IIIA: 551 (29%), IIIB: 174 (9%), and IIIC: 96 (5%), respectively (first-line daratumumab treated: 826; 43%). With a median follow-up of 34 months, median overall survival (OS) was not reached (NR); estimated 1-year, 2-year, and 3-year OS was 82%, 74%, and 70% respectively. The median survival for stages I to II, IIIA, IIIB, and IIIC were NR, 67, 26, and 7 months (1-year OS IIIC 53% v 68% for IIIB in the daratumumab-treated patients), respectively ( P < .001). External validation exhibited good predictive performance: 12-month calibration slope was 1.09, Harrell C 0.69, Royston D 1.19, and R 2 D 0.25. Stage IIIC independently discriminated the poorest outcome across all cohorts. CONCLUSION This defines and validates a new staging system from systemic AL amyloidosis with robust identification of an ultra-poor risk stage (IIIC) in contemporarily treated patients.